Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review
Top Cited Papers
- 1 March 2000
- journal article
- review article
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 20 (3) , 423-451
- https://doi.org/10.1097/00004647-200003000-00001
Abstract
Several groups have provided evidence that positron emission tomography (PET) and single-photon emission computed tomography (SPECT) neuroreceptor imaging techniques might be applied to measure acute fluctuations in dopamine (DA) synaptic concentration in the living human brain. Competition between DA and radioligands for binding to D2 receptor is the principle underlying this approach. This new application of neuroreceptor imaging provides a dynamic measurement of neurotransmission that is likely to be informative to our understanding of neuropsychiatric conditions. This article reviews and discusses the body of data supporting the feasibility and potential of this imaging paradigm. Endogenous competition studies performed in rodents, nonhuman primates, and humans are first summarized. After this overview, the validity of the model underlying the interpretation of these imaging data is critically assessed. The current reference model is defined as the occupancy model, since changes in radiotracer binding potential (BP) are assumed to be directly caused by changes in occupancy of D2 receptors by DA. Experimental data supporting this model are presented. The evidence that manipulation of DA synaptic levels induces change in the BP of several D2 radiotracers (catecholamines and benzamides) is unequivocal. The fact that these changes in BP are mediated by changes in DA synaptic concentration is well documented. The relationship between the magnitude of BP changes measured with PET or SPECT and the magnitude of changes in DA concentration measured by microdialysis supports the use of these noninvasive techniques to measure changes in neurotransmission. On the other hand, several observations remain unexplained. First, the amphetamine-induced changes in the BP of D2 receptor antagonists [123I]IBZM and [11C]raclopride last longer than amphetamine-induced changes in DA extracellular concentration. Second, nonbenzamide D2 receptor antagonists, such as spiperone and pimozide, are not affected by changes in DA release, or are affected in a direction opposite to that predicted by the occupancy model. Similar observations are reported with D1 radiotracers. These results suggest that the changes in BP following changes in DA concentration might not be fully accounted by a simple occupancy model. Specifically, the data are reviewed supporting that agonist-mediated receptor internalization might play an important role in characterizing receptor-ligand interactions. Finally, it is proposed that a better understanding of the mechanism underlying the effects observed with benzamides is essential to develop this imaging technique to other receptor systems.Keywords
This publication has 180 references indexed in Scilit:
- Kinetic evidence for isomerization of the dopamine receptor-raclopride complexNeurochemistry International, 1996
- Comparison of two radioiodinated ligands of dopamine D2 receptors in animal models: Iodobenzamide and iodoethylspiperoneLife Sciences, 1993
- Cortical regulation of subcortical dopamine systems and its possible relevance to schizophreniaJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1993
- High affinity dopamine D2 receptor radioligands. 2. [125I]epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptorsLife Sciences, 1991
- Preparation of 11C-labelled raclopride, a new potent dopamine receptor antagonist: Preliminary PET studies of cerebral dopamine receptors in the monkeyThe International Journal of Applied Radiation and Isotopes, 1985
- Trapping of labelled ligands in intact cells: A pitfall in binding studiesBiochemical Pharmacology, 1983
- Regional in vivo binding of [3H]N-propylnorapomorphine in the mouse brain. Evidence for labelling of central dopamine receptorsEuropean Journal of Pharmacology, 1981
- Invivo receptor binding: Attempts to improve specific/ non-specific ratiosLife Sciences, 1979
- In vivo binding of 3H-pimozide in mouse striatum: Effects of dopamine agonists and antagonistsLife Sciences, 1977
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973